101 related articles for article (PubMed ID: 20532440)
1. ACCORD LIPID study results strengthen guideline approach of adding fenofibrate to therapy of dyslipidaemic type 2 diabetic patients.
Aalbers J
Cardiovasc J Afr; 2010; 21(2):118-9. PubMed ID: 20532440
[TBL] [Abstract][Full Text] [Related]
2. [Lipid-lowering cardiovascular prevention in type 2-diabetes. Statins are effective according to the FIELD study].
Båvenholm P; Attvall S; Nilsson PM
Lakartidningen; 2006 Aug 30-Sep 5; 103(35):2462-6. PubMed ID: 17002161
[No Abstract] [Full Text] [Related]
3. FIELD study.
Rees A
Diabet Med; 2006 Jul; 23 Suppl 3():6-12. PubMed ID: 16805876
[No Abstract] [Full Text] [Related]
4. Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.
Steinmetz A
Diabetes Metab Res Rev; 2008; 24(4):286-93. PubMed ID: 18273835
[TBL] [Abstract][Full Text] [Related]
5. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
Fazio S
Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
[TBL] [Abstract][Full Text] [Related]
7. Fenofibrate therapy and cardiovascular protection in diabetes: recommendations after FIELD.
Vergès B
Curr Opin Lipidol; 2006 Dec; 17(6):653-8. PubMed ID: 17095910
[TBL] [Abstract][Full Text] [Related]
8. Fenofibrate and cardiovascular risk: a synopsis and commentary on (FIELD).
Bailey CJ
Diabet Med; 2006 Feb; 23(2):109-12. PubMed ID: 16433706
[No Abstract] [Full Text] [Related]
9. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
May HT; Anderson JL; Pearson RR; Jensen JR; Horne BD; Lavasani F; Yannicelli HD; Muhlestein JB
Am J Cardiol; 2008 Feb; 101(4):486-9. PubMed ID: 18312763
[TBL] [Abstract][Full Text] [Related]
10. Should we dismiss fibrates for the treatment of diabetic dyslipidaemia?
Taskinen MR
Nutr Metab Cardiovasc Dis; 2006 Dec; 16(8):509-12. PubMed ID: 17071064
[No Abstract] [Full Text] [Related]
11. Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate.
Taskinen MR; Sullivan DR; Ehnholm C; Whiting M; Zannino D; Simes RJ; Keech AC; Barter PJ;
Arterioscler Thromb Vasc Biol; 2009 Jun; 29(6):950-5. PubMed ID: 19325138
[TBL] [Abstract][Full Text] [Related]
12. Interpreting clinical trials of diabetic dyslipidaemia: new insights.
Wierzbicki AS
Diabetes Obes Metab; 2009 Mar; 11(3):261-70. PubMed ID: 17645560
[TBL] [Abstract][Full Text] [Related]
13. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
[TBL] [Abstract][Full Text] [Related]
14. Fenofibrate: treatment of hyperlipidemia and beyond.
Rosenson RS
Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1319-30. PubMed ID: 19018684
[TBL] [Abstract][Full Text] [Related]
15. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
Sorensen SV; Frick KD; Wade A; Simko R; Burge R
Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
[TBL] [Abstract][Full Text] [Related]
16. Role for fibrate therapy in diabetes: evidence before FIELD.
Vergès B
Curr Opin Lipidol; 2005 Dec; 16(6):648-51. PubMed ID: 16276243
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.
Jones PH
Am J Cardiol; 2007 Feb; 99(4A):133B-140B. PubMed ID: 17307065
[TBL] [Abstract][Full Text] [Related]
18. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.
Durrington PN; Tuomilehto J; Hamann A; Kallend D; Smith K
Diabetes Res Clin Pract; 2004 May; 64(2):137-51. PubMed ID: 15063607
[TBL] [Abstract][Full Text] [Related]
19. [The significance of fenofibrate in the therapy of atherogenic dyslipoproteinaemia].
Kucera M; Oravec S; Ocadlík I
Vnitr Lek; 2010 Aug; 56(8):865-70. PubMed ID: 20845620
[TBL] [Abstract][Full Text] [Related]
20. Fenofibrate set to benefit from new research on its active metabolite, fenofibric acid.
Cardiovasc J Afr; 2008; 19(3):171-2. PubMed ID: 18568186
[No Abstract] [Full Text] [Related]
[Next] [New Search]
